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Abstract
Heparin binding epidermal growth factor (HBEGF) is expressed in podocytes and was shown to play a role in glomerular
physiology. MicroRNA binding sites on the 39UTR of HBEGF were predicted using miRWalk algorithm and followed by
DNA sequencing in 103 patients diagnosed with mild or severe glomerulopathy. A single nucleotide polymorphism,
miRSNP C1936T (rs13385), was identified at the 39UTR of HBEGF that corresponds to the second base of the hsa-miR-
1207-5p seed region. When AB8/13 undifferentiated podocytes were transfected with miRNA mimics of hsa-miR-1207-5p,
the HBEGF protein levels were reduced by about 50%. A DNA fragment containing the miRSNP allele-1936C was cloned
into the pMIR-Report Luciferase vector and co-transfected with miRNA mimics of hsa-miR-1207-5p into AB8/13
podocytes. In agreement with western blot data, this resulted in reduced luciferase expression demonstrating the ability
of hsa-miR-1207-5p to directly regulate HBEGF expression. On the contrary, in the presence of the miRSNP 1936T allele,
this regulation was abolished. Collectively, these results demonstrate that variant 1936T of this miRSNP prevents hsa-
miR-1207-5p from down-regulating HBEGF in podocytes. We hypothesized that this variant has a functional role as a
genetic modifier. To this end, we showed that in a cohort of 78 patients diagnosed with CFHR5 nephropathy (also known
as C3-glomerulopathy), inheritance of miRSNP 1936T allele was significantly increased in the group demonstrating
progression to chronic renal failure on long follow-up. No similar association was detected in a cohort of patients with
thin basement membrane nephropathy. This is the first report associating a miRSNP as genetic modifier to a monogenic
renal disorder.
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Introduction
The inherited monogenic glomerulopathies is a genetically and
phenotypically highly heterogeneous group of conditions. Even in
specific monogenic diseases, the exact molecular pathomechanism
underlying the variable expressivity is rarely well understood. This
heterogeneity is exemplified by the observation that not all patients
who develop chronic kidney disease (CKD) due to a primary
genetic cause will proceed to end-stage kidney disease (ESKD). In
such diseases, glomerular defects that include but are not limited to
the glomerular basement membrane, the glomerular endothelium
and the podocytes can alter the kidney’s filtration barrier integrity
and lead to an adverse outcome in patients. A subset of glomerular
defects emerging from germinal mutations in specific genes or are
acquired are directly reflected on podocytes, which may lose their
structural integrity and functional properties [1,2].
Microscopic hematuria (MH) of glomerular origin can be a
benign condition persisting for life or can be the starting point of a
progressive process that may lead many years later to proteinuria
and decline of renal function resulting in CKD or ESKD [3]. A
prime example is thin basement membrane nephropathy (TBMN),
where patients in the same family who bear an identical
heterozygous mutation in either the COL4A3 or COL4A4 gene
that encodes for the a3o ra4 chain of collagen type IV
respectively, may follow a quite diverse disease course. In recent
studies on a large cohort of patients we showed that a small
percentage of patients will remain for life with benign isolated
MH; however a larger fraction of patients will proceed to
proteinuria and CKD. Overall 15–20% of patients will have an
even worse course and reach ESKD at ages after 50 years of age.
In fact, nearly 50% of patients after 50 years will require
hemodialysis or a renal transplant [4].
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2Similarly, in another recently revisited C3 glomerulopathy that
is caused by mutations in the CFHR5 gene which plays a role in
the regulation of the alternative pathway of complement
activation, nearly all patients present with MH since childhood
while they may also develop macroscopic hematuria as a response
to infections of the upper respiratory tract. A subset of patients will
remain stable but about 15%, predominantly males will develop
proteinuria and CKD or ESKD [5]. Female patients appear to
have a milder disease progression and according to our recently
published work, 14/18 patients who reached ESKD were males.
This variable expressivity might be explained by a host of factors
including genetic modifiers through yet unknown molecular
mechanisms. MicroRNA (miRNA) regulation of gene expression
could be one of these factors.
The role of miRNAs in processes such as maturation of the
mammalian kidney was recently established by the podocyte-
specific inactivation of Dicer, the RNAse III endonuclease
responsible for miRNA maturation, in mice [6,7,8]. Podocyte
foot processes were consequently depleted, while apoptosis
commenced. The affected animals initially developed albuminuria
followed by glomerular sclerosis and tubulo-interstitial fibrosis with
acute renal disease progression and eventually death of mice by 6–
8 weeks. The pathological phenotype was completed by
proteinuria, glomerular basement membrane abnormalities and
mesangial expansion, assimilating a congenital glomerulopathy.
This proves that miRNAs have a fundamental role in regulating
kidney physiological development; hence they must have a role in
renal disease as well.
miRNAs belong to the most abundant class of small RNAs in
animals. It is a recently discovered class of eukaryotic,
endogenous, non-coding RNAs that play a key role in the
regulation of gene expression. When mature they are short,
single-stranded RNA molecules approximately 21–23 nucleotides
in length, and they are partially complementary to one or more
messenger RNA (mRNA) molecules [9]. Their main function is to
down-regulate gene expression by inhibiting translation or by
targeting the mRNA for degradation or deadenylation [10]. The
mature miRNA mainly acts by targeting a miRNA recognition
element (MRE) on an mRNA’s 39UTR and binding on it through
a Watson-Crick base-pairing manner [11]. miRNA target
recognition properties depend on its ‘seed region’, which includes
nucleotides 2–8 from the 59-end of each miRNA [12]. Base-
pairing between the 39-segment of the miRNA and the mRNA
target is not always essential for repression, but strong base-
pairing within this region can partially compensate for weaker
seed matches or enhance repression [13].
In general there are two main mechanisms by which miRNAs
can be involved in disease pathogenesis. A mutation on the
miRNA itself can render it the primary causative gene. On the
other hand, a miRNA can be indirectly involved in disease
expression if the gene it targets is defined as the causative gene.
The only evidence of a miRNA itself being the primary causative
gene came from the work of Mencia et al., in which they identified
a point mutation in the seed region of miR-96 which causes
autosomal dominant non-syndromic hearing loss [14]. An
engineered mouse model with a mutation in the seed region of
miR-96, presented a phenotype similar to the human disease
confirming the primary role of miR-96 [15]. In contrast, a miRNA
can be considered as secondary cause to the disease when a genetic
variation alters the binding of that miRNA to a causal gene.
Evidence for such mechanism was shown for miR-24 when a point
mutation that altered its binding to SLITRK1 gene was identified
in patients with Tourette syndrome [16]. Similarly, point
mutations on REEP1 which is a causative gene for hereditary
spastic paraplegia were found on the binding sites of two miRNAs
(miR-140 and miR-691) [17,18].
Involvement of miRNAs in inherited diseases is not limited to
those two mechanisms. Evidence suggests that miRNAs can act as
disease modifiers as a result of genetic variations on the precursor
molecules or the miRNA-target binding sites. Single nucleotide
polymorphisms (SNPs) can affect all states of the miRNAs’
synthesis (pri-, pre-, and mature) and alter the miRNA biogenesis
or function. Variations that alter the biogenesis of miRNAs were
associated with predispositions to various diseases including
congenital heart disease [19], schizophrenia [20], papillary thyroid
carcinoma [21] and others. Despite that, it should be noted that
genetic variations within the pre-miRNAs and specifically within
the seed-region are rare and comprise less than 1% of the miRNA-
related SNPs [22].
MicroRNA associated single nucleotide polymorphisms
(miRSNPs) found on miRNA target sites within 39UTRs of
mRNAs, are relatively common. A miRSNP can eliminate or
weaken the binding of a miRNA to its target site or increase the
binding by creating a perfect sequence match to the seed of a
miRNA that normally is not associated with the given mRNA,
provided that both miRNA and mRNA share the same tissue of
expression. In both cases the result will be a significant alteration
in protein levels. There are currently three databases available
(Patrocles, dbSMR and PolymiRTS) that compile SNPs on the
mRNA 39UTR region of human and mouse genes that create or
destroy miRNA binding sites [23,24,25].
Here we hypothesized that miRSNPs might act as genetic
modifiers predisposing to a milder or more severe disease on the
background of a primary inherited glomerulopathy, such as
TBMN and/or CFHR5 nephropathy. The initial bioinformatics in
silico analysis that was followed by extensive DNA re-sequencing
revealed one such polymorphism, SNP C1936T in the 39UTR of
HBEGF (rs13385, 39UTR+1006), that corresponds to the second
position of the seed region of miRNA hsa-miR-1207-5p. Its
significance was demonstrated by functional studies in undiffer-
entiated cultured podocytes and by association studies in two
cohorts of patients. Specifically, in the presence of a mimic for
miRNA hsa-miR-1207-5p there was down regulation of the
HBEGF expression, judged by western blot analysis. This was
corroborated by the use of luciferase sensor constructs of both
alleles, where the 1936T allele demonstrated abrogation of
miRNA binding. Most interestingly, the 1936T allele was shown
to act as a genetic modifier, as it was genetically associated with a
higher risk for progression to severe renal disease in the presence
of a primary glomerulopathy, C3 glomerulonephritis.
Methods
Patients
Patients who participated in this study were diagnosed with
TBMN or CFHR5 nephropathy and were all shown to have
inherited mutations in either the COL4A3/COL4A4 genes or the
CFHR5 gene respectively, in heterozygosity. All participants were
informed by the clinicians and signed a consent form. The project
is approved by the Cyprus National Bioethics Committee. A total
of 232 anonymous DNA samples from our DNA bank served as
controls.
TBMN patients originate from 16 large Cypriot families.
Seventy-eight of 103 patients are heterozygous for the G1334E–
COL4A3 mutation, 19 of 103 are heterozygous for the G871C–
COL4A3 mutation and 6 of 103 are heterozygous for the
c.3854delG–COL4A4 mutation [26]. Due to the slow disease
progression patients with ‘‘mild disease’’ (see below) and younger
A miRSNP and CFHR5 Nephropathy
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CFHR5 nephropathy group was comprised of 45 male and 33
female patients (born before January 1975), all sharing a common
exons 2–3 heterozygous duplication in CFHR5 gene [5]. Pedigrees
and analytical clinical data have been published in detail elsewhere
[26,27]. For both, TBMN and CFHR5 cohorts, ‘‘mildly’’ affected
patients are those having only microscopic or macroscopic
hematuria episodes (but no CKD) or hematuria plus low grade
proteinuria (,400 mg/24 hrs, but no CKD). ‘‘Severely’’ affected
patients are those having hematuria plus proteinuria .500 mg/
24 hrs or hematuria plus proteinuria plus CKD or ESKD. CKD
was defined as an elevated serum creatinine over 1.5 mg/dl.
Patients with remittent or borderline proteinuria were excluded.
Patients with a concomitant renal disease (e.g., over five years
diabetes, diabetic nephropathy, vesicoureteral reflux) or at the
extreme of body weights (outside 62 SD of the cohort mean) were
also excluded.
Gene selection
In accordance with our hypothesis we searched for SNPs in the
39UTR region of genes and specifically around the putative target
regions of respective miRNAs. Eighty five genes were selected
based on a wide spectrum of criteria. Candidate genes belong to
four general categories based on their glomerular expression, their
involvement in monogenic glomerular diseases, whether they were
previously associated with a polygenic disease that presents
secondary glomerulopathy and other genes expressed in the
kidney or elsewhere that were found to be important for renal
function or are closely related to genes selected in other categories.
Podocyte specific genes, such as NPHS1, NPHS2 or PDPN are
considered as good candidates, while polygenic diseases include
diabetes, systemic lupus erythematosus, IgA nephropathy, glomer-
ulonephritis and hypertensive nephrosclerosis. Published data
regarding kidney or glomerulus specific gene expression micro-
array experiments enriched the candidate gene list, thus including
genes coding for transcription factors, activators, structural
proteins etc. In addition, genes implicated in tubular disease like
PKD1 and PKD2 were also included.
miRNA target prediction analysis
Candidate gene names were imported into miRWalk algorithm
(www.ma.uni-heidelberg.de/apps/zmf/mirwalk) and prediction of
miRNA target sequences on their mRNA 39UTR was performed
using 7 nucleotides as the minimum seed number. A multiple
comparison using 4 additional algorithms was performed for
filtering purposes, each one working based on different sets of
properties among mRNA-miRNA targeting; TargetScan, miRan-
da, miRDB and RNA22. In search for polymorphic variants by
DNA sequencing around the miRNA target sequences, our
attention was restricted only to pairs of miRNA-mRNA targets
that were predicted by all five algorithms and gave a p-
value,0.05. This p-value was automatically calculated by the
miRWalk algorithm by using Poisson distribution and depicts the
distribution of the probability of a miRNA 59-end sequence to be
randomly paired with a given 39UTR mRNA sequence.
DNA sequencing analysis of target regions
DNA sequencing of predicted target regions was performed
using BigDye
TM V3.1 chemistry on an ABI Prism
TM Genetic
Analyzer (Applied Biosystems, California USA). Sequencing
primers (all supplied by MWG, Ebersberg, Germany) were
designed to flank the target region but also included an additional
300 bp on average on each side. Sequence electropherograms
were obtained from the ABI Sequencing Analysis
TM V5.2 software
(Applied Biosystems, California, USA) and sequences were
imported into BioEdit
TM Software to be aligned against a
reference sequence with ClustalW algorithm [28]. SNPs that were
identified in positions other than the predicted ones were
evaluated using the miRanda tool (http://www.microrna.org)
and cross-referenced with initial predictions.
Expression reporter system constructs
To evaluate the binding efficiency of miRNAs onto predicted
target sequences, the pMiR-REPORT
TM miRNA Expression
Reporter Vector System (AMBION, Texas, USA) was used. For
the case where we identified a SNP in the 39UTR region, each
allele was obtained with a polymerase chain reaction (PCR)
amplification from two patients, each one homozygous for either
allele and primers were designed to introduce a SpeI and a HindIII
restriction enzyme sites to be cloned into the pMiR-REPORT
TM
Luciferase vector. For rs13385, the insert included 297 bp of
HBEGF 39UTR that flanked the SNP. Ligation products were
transformed into competent DH5a E. coli cells (Takara, Japan).
Insert verification included a restriction reaction with SpeI and
HindIII and sequencing using 100 ng of DNA.
Transfection of AB8/13 podocytes
The AB8/13 undifferentiated podocyte cells, supplied by Dr
Moin A. Saleem [29], were incubated at 33uCa t5 %C O 2 and
cultured in RPMI medium, supplemented with 10% Fetal Bovine
Serum (FBS) (Invitrogen, California, USA), 1% of 100 units/ml
Penicillin/Streptomycin (Invitrogen, California, USA) and 1%
Insulin-Transferrin-Selenium (Invitrogen, California, USA). For
the luciferase reporter system experiments, AB8/13 cells were
triply transfected with equal amounts of the pMIR-REPORT
TM
Luciferase and b-gal vectors and 25 nM of miScript
TM hsa-miR-
1207-5p mimic (QIAGEN, West Sussex, UK) or the AllStars
TM
Negative Control scrambled sequence LNA (QIAGEN, West
Sussex, UK), using Lipofectamine 2000 (Invitrogen, California,
USA). The b-gal vector was used for normalization. Every
experiment was performed in triplicates in 6-well cell culture
plates with the appropriate controls. Cells were harvested 12 h
after transfection. The Dual-Light Assay
TM Kit (Applied Biosys-
tems, Caifornia USA) was used for the quantification of both
luciferase and b-gal in an automated luminometer (Sirius,
Berthold Detection Systems, Pforzheim, Germany). For western
blot experiments, AB8/13 cells were transfected with 25 nM of
miScript
TM hsa-mir-1207-5p mimics and inhibitors, as well as with
AllStars
TM Negative Control scrambled sequence LNA (QIA-
GEN, West Sussex, UK) for 16 hours.
Western blot experiments
AB8/13 cells were lysed in equal volumes of pre-heated 2xSDS
loading buffer (Sodium Dodecyl Sulphate–125 mM Tris-HCl
pH 6.8, 20% Glycerol, 2% SDS, 2% b-mercaptoethanol and
bromophenol blue) and homogenized using a 2 ml syringe. Whole
cell lysates were subsequently electrophoresed in a 12% SDS-
Polyacrylamide gel. Gel transfer was held in a wet transfer system
on Hybond Polyvinylidene Fluoride (PVDF–Millipore, Massachu-
setts, USA) membranes. Membranes were blocked with 5% non-
fat dry milk in PBS/0.01% Tween20 for 1 hour at room
temperature. Primary antibody was diluted in milk and added to
the membrane for one hour. HBEGF protein was detected with
the murine primary monoclonal antibody G-11 (SantaCruz
Biotechnology, California, USA) at around 24 kDa. b-Tubulin
was used as loading control by using the T-4026 primary antibody
(SIGMA, Taufkirchen, Germany). As secondary antibody we used
the rabbit anti-mouse antibody (SantaCruz Biotechnology,
A miRSNP and CFHR5 Nephropathy
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Proteins were detected using the Enhanced ChemiLuminescence
(ECL) Plus Blotting Detection system (Amersham Biosciences,
Buckinghamshire, UK) and were visualized by autoradiography
on photographic film (KODAK X-OMAT, New York, USA).
Band density was defined by ImageJ Software (http://imagej.nih.
gov/ij).
Real-Time PCR for miRNA detection
To examine the endogenously expressed levels of hsa-miR-
1207-5p, total RNA enriched in small RNAs was isolated from
AB8/13, HEK293 and SHSY-5Y neuroblastoma cells using the
miRNeasy Mini Kit (QIAGEN, West Sussex, UK). MiRNA
specific reverse transcription was performed with the miScript
TM
Reverse Transcription Kit (QIAGEN, West Sussex, UK). Real-
Time PCR was performed on a Roche Lightcycler (Roche
Diagnostics, Indianapolis, USA) using the miScript
TM SYBRH
Green PCR Kit (QIAGEN, West Sussex, UK), according to the
manufacturers protocol. Detection of mature hsa-miR-1207-5p
was accomplished using miScript
TM Assay primers, supplied by
QIAGEN. MiRNA enriched total RNA from human renal
epithelial cells (HREpiC) was supplied by ScienCell (California,
USA). Each experiment was performed twice in duplicates and
miScript
TM Hs_SNORA73A_1 small RNA was used as reference,
with primers supplied from QIAGEN.
Genotyping of miRSNP C1936T
Genotyping for the C1936T SNP was performed in all
samples, either by direct re-sequencing (TBMN samples) or by
restriction reaction analysis (CFHR5 and healthy control
samples). For this purpose, a restriction recognition site for BsrI
was engineered in the forward PCR primer, by substituting the
penultimate T by an A (Forward primer: 59- CAA AGT GTA
ACA GAT ATC AGT GTC TCC CCG TGT CCT CTC CCA
G–3 9, Reverse Primer: 59- GCT TTG CTA ATA CCT TCT
CCA GAC TGT CCT CTG CTG CAC TGA -39). The
recognition site is created upon PCR amplification of the T allele.
Subsequent sequencing analysis of selected samples confirmed the
validity of this test. In addition, C1936T was also analyzed in the
AB8/13 cell line by sequencing analysis, demonstrating a CC
homozygous genotype.
Statistical analysis
Genotyping results were statistically evaluated using two-sided
Barnard’s unconditional test of superiority, as it was shown that it
is more powerful for 262 contingency tables with limited
observations than conventional conditional tests [30,31,32]. The
reported Wald statistic is the standardized difference between the
two binomial proportions of each category [30]. For the analysis of
contingency tables we used StatXact 9 (Cystat, Cambridge, MA,
USA) [33], as suggested in a publication by Ludbrook J. (2008)
[34]. In order to provide an open-source alternative for
performing the Barnard’s test, the ‘‘Barnard’’ package has been
developed for the statistical scripting language R. The Barnard
package is included in the Comprehensive R Archive Network
(http://cran.r-project.org/web/packages/Barnard), where it is
freely available for download and immediate use by anyone.
C1936T was tested for Hardy-Weinberg equilibrium using
Pearson’s chi-square test in controls. Luciferase expression levels
were analyzed using one-way non-parametric ANOVA after being
normalized against b-gal expression levels. One-way ANOVA was
also used to test densitometry results from western blot analyses,
followed by Tukey post-testing.
Results
Bioinformatic analysis for identification of miRNAs as
modifiers of glomerulopathies
Heritable monogenic glumerulopathies that present with MH
display interfamilial and intrafamilial phenotypic heterogeneity,
thereby suggesting the involvement of modifier genes in disease
progression [35]. We herewith hypothesized the putative role of
miRNAs as disease modifiers and we searched for functional
polymorphic variants in the predicted target sites of miRNAs for
genes expressed or located in the glomerulus. To this end, we
guided our search for SNPs within the miRNA target sites of genes
selected as described in Methods. Expression in podocytes,
localization in the slit diaphragm and the glomerulus basement
membrane rendered genes as good candidates for our study.
With the use of miRWalk (http://www.ma.uni-heidelberg.de/
apps/zmf/mirwalk) and four other prediction algorithms (miR-
Base, TargetScan, miRDB and RNA22), we looked for validated
miRNAs that target the candidate genes. We narrowed down the
candidates of interest by selecting only miRNA-mRNA pairs that
were predicted by all five algorithms (Table 1).
Identification of candidate SNPs by sequence analysis
A segment of about 500–600 nts encompassing the miRNA
binding site in the 39UTR of selected genes, was re-sequenced in
103 patients with TBMN, classified as severe or mild. Table 2
summarizes the results of the sequencing analysis depicting the
gene sequenced, the miRNA predicted to bind to the 39UTR of
that gene and the SNPs identified. Although various SNPs were
identified in the group of patients sequenced, none was located on
the predicted miRNA binding sites. However, a SNP was
identified in the binding site of another miRNA that was originally
excluded due to a lower significance compared to top candidates.
Specifically, while sequencing around the hsa-miR-379 target site
in the HBEGF 39UTR, we identified a biallelic variation of C or T
at position 1936 (C1936T) in the target region of hsa-miR-1207-
5p which is also predicted to target HBEGF. The C1936T SNP is
found at what corresponds to position 2 of the ‘seed’ region of hsa-
miR-1207-5p (Fig. 1A) suggesting a possible elimination or severe
compromise of the ability of this miRNA to bind on HBEGF
mRNA.
Verification of functional significance by in vitro
experimentation
In order to verify whether HBEGF is a true target of hsa-miR-
1207-5p and that the presence of C1936T SNP alters the binding
and regulation incurred by the miRNA, we performed luciferase
‘sensor’ assays. A segment of the HBEGF 39UTR containing the
1936C (pMIR-REPORT-HBEGF-1936C) or 1936T (pMIR-
REPORT-HBEGF-1936T) variant was cloned into the 39UTR
of the luciferase gene in pMIR-REPORT plasmid. Reporter
plasmids and b-gal reference plasmid were co-transfected in AB8/
13 podocyte cell line with either hsa-miR-1207-5p mimic or
negative control mimics for 12 hours followed by luciferase and b-
gal measurement. Co-transfection of hsa-miR-1207-5p mimics
with the pMIR-REPORT-HBEGF-1936C resulted in significant
reduction in luciferase expression (47.14%+/20.42 SEM of
normalized RLU relative to control) demonstrating that this
miRNA directly binds on HBEGF 39UTR region (Fig. 1B). In
agreement, transfection of hsa-miR-1207-5p mimics in AB8/13
cells significantly reduced the endogenous levels of HBEGF
protein as demonstrated by Western blot analysis at about 20%
of total expression, while hsa-miR-1207-5p inhibitors boosted
HBEGF levels by reducing the endogenously expressed miRNA
A miRSNP and CFHR5 Nephropathy
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significant decrease or increase of HBEGF levels on mimic or
inhibitor transfection respectively. (Fig. 1C, lower panel).
On the contrary, in the presence of pMIR-REPORT-HBEGF-
1936T, transfection of hsa-miR-1207-5p mimics did not signifi-
cantly alter luciferase expression (90.56%+/23.8 SEM of normal-
ized RLU relative to control) in AB8/13 cells (Fig. 1B). Combined
these results demonstrate that hsa-miR-1207-5p can directly
regulate HBEGF expression and this regulation is abolished if there
is a T nucleotide at position 1936 of HBEFG’s 39UTR.
Table 1. Prediction results using five different miRNA-target prediction tools.
GENE miRNA RNA22 miRANDA miRDB miRWalk TargetScan SEED LENGTH START SEQUENCE END p-VALUE
PDPN hsa-mir-485-5p 33 33 3 8 1453 AGAGGCUG 1446 0.031
HBEGF hsa-mir-212 33 33 3 9 1584 UAACAGUCU 1576 0.0056
HBEGF hsa-mir-132 33 33 3 10 1584 UAACAGUCUA 1575 0.0014
HBEGF hsa-mir-379 33 33 3 8 1833 UGGUAGAC 1826 0.0223
FN1 hsa-mir-96 33 33 3 8 8340 UUUGGCAC 8333 0.0169
FN1 hsa-mir-144 33 33 3 9 8331 UACAGUAUA 8323 0.0042
GJA1 hsa-mir-495 33 33 3 8 2244 AAACAAAC 2237 0.0261
PKD2 hsa-mir-183 33 33 3 8 4768 UAUGGCAC 4761 0.0315
PKD2 hsa-mir-372 33 33 3 9 4022 AAAGUGCUG 4014 0.008
PPARA hsa-mir-223 33 33 3 9 5877 UGUCAGUUU 5869 0.0314
SP1 hsa-mir-24 33 33 3 7 5240 UGGCUCA 5240 0.2725
SP1 hsa-mir-31 33 33 3 9 6960 AGGCAAGAU 6952 0.0197
SP1 hsa-mir-105 33 33 3 7 5548 UCAAAUG 5542 0.2725
SP1 hsa-mir-155 33 33 3 8 2560 UUAAUGCU 2553 0.0764
TJP1 hsa-mir-144 33 33 3 8 6469 UACAGUAU 6462 0.0218
Ticks under algorithm names indicate the successful prediction of each miRNA-mRNA pair per prediction tool. ‘‘Start’’ and ‘‘end’’ columns state the exact position of the
putative miRNA target region on the 39UTR of the respective mRNA. Numbering refers to position from the start of the mRNA 39UTR. For sequencing analysis, pairs that
had p-values of less than 0.05 were selected.
doi:10.1371/journal.pone.0031021.t001
Table 2. Results after re-sequencing of 103 samples with mutations in COL4A3 or COL4A4 genes and thin basement membrane
nephropathy.
GENE miRNAs
miRNA
POSITION PCR AND SEQUENCING PRIMERS PREDICTION HITS SNPs FOUND NOTES
PDPN hsa-mir-485-5p 1453-1446 59- GTTAGGGCAGGTGGGATG -39
59- TGTATGCGGCTGGTAAGTAG -39
5/5 T1226A
G1545A
G1262A
1251DEL-G
SNPs not on
miRNA target sites
HBEGF hsa-mir-132
hsa-mir-212
1584-1575
1584-1576
59- TGAACTGGAAGAAAGCAACA -39
59- ACCCCTACATCCTGACCATAC -39
5/5 None No SNPs found
HBEGF hsa-mir-379 1833-1826 59- ACTCCTCATCCCCACAATCT -39
59- CCCACCTCCAACCTTCTC -39
5/5 C1936T SNP found at neighboring
position, which is target
for hsa-miR-1207-5p
FN1 hsa-mir-96
hsa-mir-144
8340-8332
8331-8322
59- TTGGGATCAATAGGAAAGCA -39
59- GAAGAGATGAAGTGACAAAAACC -39
5/5 None No SNPs found
PKD2 hsa-mir-183 4768-4760 59- TCCAGGTTGAAAGTGAAAC -39
59- CAGGGAAAGATAATAGGGAAGA -39
5/5 None No SNPs found
PKD2 hsa-mir-372 4022-4014 59- TTCCCATGTGGCTCTACTCA -39
59- AGACCCTCTCGTAAAGAAAACA -39
5/5 G4003A
G4210A
SNPs not on
miRNA target sites
PPARA hsa-mir-223 5877-5868 59- GTTAGGGCAGGTGGGATG -39
59- TGTATGCGGCTGGTAAGTAG -39
5/5 None No SNPs found
SP1 hsa-mir-31 6960-6951 59- GACTTCCCCAAACCCAGA -39
59- CACCCATCCCTTCCAGAG -39
5/5 None No SNPs found
TJP1 hsa-mir-144 6469-6462 59- GGAGGGTGAAGTGAAGACAA -39
59- GCATAGCCAGAAAGAACAGAA -39
5/5 A6485C SNPs not on
miRNA target sites
Sequencing primers were designed to flank the predicted target sites and also include about 300 bp on either side. Prediction hits represent the number of tools that
successfully predicted the miRNA-mRNA binding.
doi:10.1371/journal.pone.0031021.t002
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PLoS ONE | www.plosone.org 6 February 2012 | Volume 7 | Issue 1 | e31021The hsa-miR-1207-5p is highly enriched in podocytes as
demonstrated by miRNA specific Real-Time PCR experiments.
Specifically, miR-1207-5p is expressed 2-fold higher in differen-
tiated AB8/13 podocytes, compared to undifferentiated cells
(Fig. 2). In addition, human renal epithelial cells express 4-fold
higher miR-1207-5p than differentiated AB8/13 cells. Other cell
lines, such as HEK293 and SHSY-5Y demonstrate limited
expression levels of miR-1207-5p when compared to podocytes.
Genotyping results
We then tested the hypothesis that this variant may act as a
genetic modifier in two cohorts of patients with inherited
monogenic glomerulopathies. From 232 control subjects that were
genotyped, 70% were CC homozygotes, 27% CT heterozygotes
and 3% TT homozygotes. The control population obeys the
Hardy-Weinberg equilibrium (p=0.812), as tested by the
Pearson’s chi-square test. Sequencing analysis showed that
68.2% of patients having mild TBMN are homozygous for the
C allele, 6.8% are homozygous for the T allele and 25%CT
heterozygotes (Table 3). As regards patients with severe TBMN
disease, 76.3% were CC homozygotes, 1.7% TT homozygotes and
22% CT heterozygotes. There was no statistical significance
between the two groups, upon two-sided Barnard’s testing (p-
value=0.368). We then tested a separate cohort of 78 patients
diagnosed with CFHR5 nephropathy. Among 45 CHFR5 patients
with milder disease progression, 86.6% are homozygous for the C
allele, while the remaining are CT heterozygotes. In contrast,
63.6% of the 33 severely affected CFHR5 patients are CC
homozygotes and 36.4% are CT heterozygotes. Barnard’s test
with a 95% confidence interval revealed an association between
mild CFHR5 and the CC genotype, with a p-value of 0.018 and
Wald statistic of 22.385 (Fig. 3).
Further grouping of TT homozygotes and CT heterozygotes,
indicated a significant difference between mild CFHR5 patients
and mild TBMN patients with a p=0.0.038 after Barnard’s test
with a Wald statistic of 2.089. The corresponding frequencies did
not differ significantly between severe CFHR5 and severe TBMN
patients. Collectively, evidence suggests that the CT/TT genotype
has no significant effect on the severity of TBMN, but it increases
the risk for a severe outcome in patients with CFHR5
nephropathy, by 3.7 times.
A separate evaluation of women in our CFHR5 cohort,
revealed significance between mildly and severely affected women
with a p-value of 0.035 and a Wald statistic of 22.234 (Fig. 4). As
women are known to have a milder course of the disease, it is 8
times more likely to have a severe phenotype if the patient is a
female and a carrier of a CT/TT genotype.
Discussion
The phenotypic heterogeneity and variable expression, exem-
plified as a broad spectrum of symptoms in a cohort of patients, is
the norm in many monogenic disorders including renal conditions,
such as glomerulopathies. The role of genetic modifiers, at least
partly, is frequently invoked as they are hypothesized to act in
symphony with a validated mutation in a single gene. For
example, recent publications have reported several occasions
Figure 1. Effect of C1936T miRSNP in HBEGF gene on regulation by hsa-miR-1207-5p, in a podocyte culture system. A) Schematic
depicting the position of miRSNP C1936T on the target region of hsa-miR-1207-5p on HBEGF. This miRSNP corresponds to the second base of the
seed region of hsa-miR-1207-5p, underlined C. B) Normalized luciferase relative light units (RLUs) in AB8/13 cell lysates after transfection with sensor
constructs. Co-transfection of the pMIR-REPORT-HBEGF-1936C with hsa-miR-1207-5p miRNA LNA mimics resulted in significant reduction of luciferase
expression, with a p-value of 0.0026 using one-way non-parametric ANOVA test. In contrast, the pMIR-REPORT construct bearing the 1936T allele
(pMIR-REPORT-HBEGF-1936T) abolished the hsa-miR-1207-5p binding site as demonstrated from the loss of RLU reduction. Results represent mean
values of triplicates 6 SEM. C) Western blot of HBEGF from AB8/13 cells after transient transfection with hsa-miR-1207-5p miRNA LNA mimics,
inhibitors and the AllStars
TM Negative Control scrambled sequence LNA. This is a representative of six experiments. Lower panel presents the
statistical analysis of western blot densitometry results, normalized against the Negative Control. Values represent the mean 6 SEM. Results illustrate
the reduction of HBEGF protein levels at the presence of hsa-miR-1207-5p mimics (p=0.014), while miRNA inhibitors significantly increased HBEGF
levels (p=0.024).
doi:10.1371/journal.pone.0031021.g001
Figure 2. Expression analysis of miR-1207-5p in various cell
lines. Relative expression analysis of mature hsa-miR-1207-5p levels in
various cell types, as tested by miRNA specific Real-Time PCR
experiments. Both AB8/13 differentiated and undifferentiated podo-
cytes revealed significantly high expression levels of miR-1207-5p,
compared to HEK293 and SHSY-5Y neuroblastoma cells. Further
examination of miR-1207-5p levels in human renal epithelial cells
(HREpiC), recorded 4-fold higher mature miRNA than the AB8/13
differentiated podocyte cell line. Results represent the mean of
quadruplicate values 6 SEM.
doi:10.1371/journal.pone.0031021.g002
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pathology, for example a SNP in the DKK3 gene or in the eNOS
gene in polycystic kidney disease [36,37,38].
Having in mind recent advances in our understanding of
molecular pathogenetic mechanisms, it is reasonable to expect that
one other class of modifiers, among others, could be sequence
variations on the target sites of miRNAs, in genes whose function
relates to the disease under study. Inheritance of such variants is
not expected to cause a disease in a Mendelian fashion; however
their stochastic co-segregation with a primary disease-causing
mutation may affect the risk for slower or faster progression of the
phenotype. A mutation in a miRNA gene itself that is responsible
for a Mendelian phenotype has been reported once, to our
knowledge, whereas several publications report on the presence of
pathology-associated variants in the target sites of known miRNAs.
At the same time miRNAs can act as disease modifiers as a result
of genetic variations on the precursor molecules. Specifically,
Table 3. Genotype and allele frequencies in all study groups.
GENOTYPE/ALLELE
MILD TBMN
(COL4A3/COL4A4
MUTATIONS)
SEVERE TBMN
(COL4A3/COL4A4
MUTATIONS)
MILD CFHR5
NEPHROPATHY
SEVERE CFHR5
NEPHROPATHY
CC 30 68.2% 45 76.3% 39 86.6% 21 63.6%
CT 11 25% 13 22% 6 13.4% 12 36.4%
TT 3 6.8% 1 1.7% 0 0% 0 0%
CT/TT 14 31.8% 14 23.7% 6 13.4% 12 36.4%
Under each group label, left columns demonstrate the number of subjects for each genotype and allele, while right columns the respective percentages.
doi:10.1371/journal.pone.0031021.t003
Figure 3. Mildly affected CFHR5 patients have lower occur-
rence of the 1936T allele. Graphical representation of both TBMN
and CFHR5 nephropathy cohorts used in this study in relation to the
number of CT and TT patients. Nephropathy patients with mild CFHR5
have significantly lower perce n t a g eo ft h eC Tg e n o t y p ew h e n
compared with severe CFHR5 patients (p=0.018), indicating a
protective effect of the CC genotype. Statistical comparison between
mild TBMN and mild CFHR5 patients demonstrated a significant
underrepresentation of the 1936T allele in mild CFHR5 patients
(p=0.038). Mild TBMN patients did not differ from severe TBMN
patients (p=0.368). All statistical analyses were performed using two-
sided Barnard’s test.
doi:10.1371/journal.pone.0031021.g003
Figure 4. The 1936C/T HBEGF genotype is overrepresented in
women affected with severe CFHR5. Comparison of C1936T
genotypes in women manifesting CFHR5 nephropathy. Women are
known to have a milder course of the disease when compared to men
and this is also demonstrated when they are statistically compared with
severe CFHR5 women as regards the C1936T SNP. The 1936C allele has
a significantly lower representation in severe CFHR5 women, compared
to mild women, thus suggesting a protective effect for this allele
(p=0.035).
doi:10.1371/journal.pone.0031021.g004
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mature miRNA. Such SNPs may affect either the biogenesis or the
action of the mature miRNA, contributing to deregulation of
target gene expression and consequently to disease development
[39]. Notwithstanding this situation, most common are the
miRNA-associated single nucleotide polymorphisms (miRSNPs)
that are located in the miRNA target sites within the 39UTRs of
corresponding mRNAs. Several studies have identified associations
of miRSNPs with complex trait diseases such as diabetes [40],
asthma [41], Parkinson [42], hypertension [43], breast cancer with
early age at onset [44] and others.
In this report, we show data according to which a reduction
of hsa-mir-1207-5p binding ability on its target site in the
39UTR of HBEGF due to the presence of C1936T SNP is
associated with the severity of CFHR5 nephropathy in patients
inheriting the pathogenic CFHR5 gene duplication of exons 2–3.
To our knowledge this is the first time a miRSNP is shown to be
correlated with the phenotypic manifestation of a monogenic
glomerular disease. Specifically, we showed that in a cohort of
patients inheriting this CFHR5 nephropathy, the 1936C allele
at the binding site for miRNA hsa-miR-1207-5p is associated
w i t hal e s ss e v e r ep h e n o t y p e ,a st h i si se x e m p l i f i e di np a t i e n t s
who are protected from the development of high grade
proteinuria and CKD (p=0.018, Fig. 3). When concentrating
on the subgroup of women, only three of 27 with mild disease
inherited the T allele, compared to three of six women with
severe disease (Fig. 4). This finding obtains particular signifi-
cance in view of the fact that women follow a much milder
course of disease compared to men, according to a previous
work of our group [5,27]. The exact mechanism by which
HBEGF can alter disease phenotype is currently unknown and
under investigation. However, we hypothesize that the role of
HBEGF in proliferation and fibrosis of mesangial cells is very
critical to this end. In support of its functional significance, we
showed in cell culture experiments that the presence of the T
allele eliminates the binding of the miRNA, thus resulting in
higher HBEGF protein levels (Fig. 1).
We undertook a rather difficult approach to identify such a
SNP, by collecting genes from the literature that are known to be
involved in glomerular structure and function. In order to narrow
down our search we utilized prediction algorithms in an attempt
to extract the best candidate genes for sequence. In our case, the
hsa-miR-1207-5p was predicted by two out of five algorithms to
target HBEGF. Although not a top candidate, luckily enough hsa-
miR-1207-5p target site is positioned nearby a site for an alleged
good candidate miRNA (hsa-miR-379). As a result, we managed
to prove the functional interaction of hsa-miR-1207-5p with
HBEGF, because the cell culture experiments as well as the
statistical evaluation in our cohort of patients supported its
implication in gene regulation at post-transcription level. This
case is a prime example where despite the improvement in
bioinformatics tools and methods for predicting miRNA targets,
some valuable information can still escape. The systematic
approach we used however, along with the flexibility of our
tools, enabled us to identify a functional SNP that otherwise
would have been missed.
HBEGF belongs to the epidermal growth factor superfamily. It
is also known as the Diphtheria toxin receptor since it is required
for the surface binding of diphtheria toxin and entry into the cell
[45]. This growth factor is expressed at high levels in podocytes,
tubular epithelial cells and mesangial cells [46]. Several studies
have emphasized the role of HBEGF in kidney function under
normal or pathologic conditions. Ischemia/reperfusion (IR) injury
was shown to be mediated by HBEGF, as reduction in expression
of this protein had a protective effect in various IR models [45,47].
As a member of a growth factor family, HBEGF can promote
cellular proliferation in both mesangial and renal epithelial cells.
Specifically, studies using renal proximal tubular cells revealed that
proliferation in this cell type is mediated by HBEGF through an
autocrine/paracrine mechanism which antagonizes the action of
Src kinases [48]. In addition, HBEGF is expressed in mesangial
cells and is involved in mesangial cells proliferation in glomeru-
lonephritis and contributes to lesion formation in focal glomerular
sclerosis through stimulation of mitogens at those sites [49,50].
Similarly, HBEGF participates in renal fibrosis by regulating both
TGF-b-mediated fibronectin expression and collagen expression
in mesangial cells [51].
In humans, the miR-1207-5p is transcribed from the PVT1
locus on chromosome 8q24 [52]. The PVT1 gene is encoding for a
non-translated RNA and has been found to be implicated in
diabetic nephropathy and breast and colon cancer, in transloca-
tions related to Burkitt’s lymphoma and associated with Hodgin’s
lymphoma [53,54,55,56]. Interestingly, end-stage renal disease
occurring in patients with diabetes type 2 has been associated with
PVT1, while variants in the same gene were associated with
ESKD in patients with type 1 diabetes [57,58]. A recent study by
Alvarez and DiStefano investigated PVT1 properties in depth and
confirmed its high expression in mesangial cells, as well as
proposed an up-regulation in the levels of the miRNAs emerging
from PVT1 by elevated glucose in the mesangium [53]. These
findings can supplement the results of our study and together are
suggestive of novel roles for PVT1 influenced miR-1207-5p
expression and translational regulation of HBEGF in terms of
maintaining the physiological function of the mesangium or the
glomerulus in general.
In conclusion, we presented evidence for the novel genetic
modifier role of miRNA hsa-miR-1207-5p in predisposing patients
with a monogenic recently described CFHR5 nephropathy, to
more severe phenotype. The fact that all our patients shared the
same exact germinal mutation probably was a factor that
facilitated the identification of this modifier, as there was no
confounding allelic heterogeneity. At the same time our data
implicate HBEGF as the gene through which this miRNA exerts its
effect. Further work at the cellular level and perhaps with the use
of animal models will help elucidate in more detail the exact
mechanism by which this hsa-miR-1207-5p/HBEGF pair plays its
role. Notwithstanding our positive results and conclusions, it does
not escape our attention that our cohorts are somewhat small. At
this point in time it is impossible to enlarge the relevant cohort or
to derive a new one before the passage of many years. Also, to our
knowledge no patients have been diagnosed yet, of a different
ethnic origin, as the C3 glomerulonephritis caused by a CFHR5
mutation appears endemic to Cyprus.
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